1281922-85-7

Upstream product

• 1281922-74-4 6-(tert-butyldiphenylsilanyloxymethyl)-2,2-dimethyltetrahydrocyclopenta[1,3]dioxol-4-one 
• 1281922-76-6 6-(tert-butyldiphenylsilanyloxymethyl)-2,2-dimethyltetrahydrocyclopenta[1,3]dioxol-4-ol 
• 303963-92-0 (3aR,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-one 

Downstream Products

• 1281922-72-2 (4-tert-butoxy-2,2-dioxo-tetrahydro-2-yl-6-cyclopenta[1,3,2]-dioxathiol-5-ylmethoxy)-tert-butyl-diphenyl-silane 
• 905579-51-3 MLN4924 
• 905579-51-3 ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)-methyl sulfamate 
• 1281922-80-2 2-tert-butoxy-3-(tert-butyl-diphenyl-silanyloxymethyl)-5-[4-(indan-1-ylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclopentanol 
• 1281922-81-3 {7-[3-tert-butoxy-4-(tert-butyl-diphenyl-silanyloxymethyl)-cyclopentyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-indan-1-yl-amine 
• 1281922-90-4 C₄₈H₅₄N₄O₄SSi 

Relevant academic research and scientific papers

PREPARATION METHOD OF MLN4924 AS AN E1 ACTIVATING INHIBITOR

The present invention relates to a method for preparation of MLN4924 as an E1 activating inhibitor, and more specifically, to a method for efficient and stereoselective preparation of MLN4924 by means of key steps involving stereoselective reduction of cy

Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme

MLN4924 (1), which is in clinical trials as an anticancer agent, was stereoselectively synthesized from d-ribose via a route involving stereoselective reduction, regioselective cleavage of an isopropylidene moiety, and selective displacement of a cyclic s